

Amendments to the Claims:

Claims 1-19 (canceled)

20. (Currently amended) A method of treating non-Hodgkin's B-cell lymphoma in a human subject, said method comprising administering to said subject at least one therapeutically effective dose of an anti-CD20 antibody or fragment thereof in combination with daily subcutaneous administration of ~~at least one a~~ therapeutically effective dose of human interleukin-2 (IL-2) or biologically active variant thereof, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 125 mg/m<sup>2</sup> to about 500 mg/m<sup>2</sup> and said therapeutically effective dose of said IL-2 or variant thereof is in the range from 3 mIU/m<sup>2</sup> to ~~14 mIU/m<sup>2</sup>~~ 6 mIU/m<sup>2</sup>, ~~and wherein said variant of human IL-2 has the ability promote natural killer (NK) cell expansion and function, said variant having an amino acid sequence having at least 90% sequence identity to the full-length amino acid sequence for human IL-2.~~

21. (Currently amended) The method of claim 20, wherein said therapeutically effective dose of said IL-2 or variant thereof is ~~in the range from 3 mIU/m<sup>2</sup> to 12 mIU/m<sup>2</sup>~~ about 3.5 mIU/m<sup>2</sup>.

22. (Currently amended) The method of claim ~~21~~ 20, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225 mg/m<sup>2</sup> to about 400 mg/m<sup>2</sup> ~~and wherein said therapeutically effective dose of said IL-2 or variant thereof is in the range from 3 mIU/m<sup>2</sup> to 6 mIU/m<sup>2</sup>~~.

23. (Previously presented) The method of claim 22, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is about 375 mg/m<sup>2</sup> and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 3.5 mIU/m<sup>2</sup>.

24. (Currently amended) The method of claim 22, wherein said ~~therapeutically effective dose of said anti-CD20 antibody of fragment thereof is in the range from about 225 mg/m<sup>2</sup> to about 400 mg/m<sup>2</sup> and~~ wherein said therapeutically effective dose of said IL-2 or variant thereof is about 6 mIU/m<sup>2</sup> 3.5 mIU/m<sup>2</sup>.

25. (Canceled)

26. (Previously presented) The method of claim 20, wherein said IL-2 or variant thereof is administered as a pharmaceutical composition selected from the group consisting of a monomeric IL-2 pharmaceutical composition, a multimeric IL-2 composition, a lyophilized IL-2 pharmaceutical composition, and a spray-dried IL-2 pharmaceutical composition.

27. (Canceled)

28. (Previously presented) The method of claim 20, wherein said variant is des-alanyl-1, serine-125 human IL-2.

29. (Previously presented) The method of claim 20, wherein said anti-CD20 antibody is an immunologically active chimeric anti-CD20 antibody.

30. (Previously presented) The method of claim 29, wherein said chimeric anti-CD20 antibody is IDEC-C2B8.

31. (Currently amended) A method of treating non-Hodgkin's B-cell lymphoma in a human subject, wherein said method comprises administering at least one therapeutically effective dose of an anti-CD20 antibody or fragment thereof to said subject beginning on day 1 of a treatment period followed by daily subcutaneous administration of at least one a therapeutically effective dose of human interleukin-2 (IL-2) or biologically active variant thereof to said subject within 7 days, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 125 mg/m<sup>2</sup> to about 500 mg/m<sup>2</sup> and wherein said therapeutically effective dose of said human IL-2 or variant thereof is in the range from 3 mIU/m<sup>2</sup> to ~~44 mIU/m<sup>2</sup>~~ 6 mIU/m<sup>2</sup>, and wherein said variant of human IL-2 has the ability to promote NK cell expansion and function, said variant having an amino acid sequence having at least 90% sequence identity to the full-length amino acid sequence for human IL-2.

32. (Previously presented) The method of claim 31, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is administered once a week for a period of 4 weeks, and said therapeutically effective dose of said IL-2 or variant thereof is administered daily beginning on day 8 of said treatment period.

33. (Previously presented) The method of claim 32, wherein said therapeutically effective dose of said IL-2 or variant thereof is administered daily for a period of 4 weeks beginning on day 8 of said treatment period.

34. (Currently amended) The method of claim ~~33~~ 31, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225 mg/m<sup>2</sup> to about 400 mg/m<sup>2</sup> ~~and wherein said therapeutically effective dose of said IL-2 or variant thereof is in the range from 3 mIU/m<sup>2</sup> to 6 mIU/m<sup>2</sup>.~~

35. (Previously presented) The method of claim 34, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is about 375 mg/m<sup>2</sup> and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 3.5 mIU/m<sup>2</sup>.

36. (Withdrawn - currently amended) The method of claim 31A method of treating non-Hodgkin's B-cell lymphoma in a human subject, wherein said method comprises administering at least one therapeutically effective dose of an anti-CD20 antibody or fragment thereof to said subject beginning on day 1 of a treatment period followed by subcutaneous administration of at least one therapeutically effective dose of human interleukin-2 (IL-2) or biologically active variant thereof to said subject within 7 days, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 125 mg/m<sup>2</sup> to about 500 mg/m<sup>2</sup> and wherein said therapeutically effective dose of said human IL-2 or variant thereof is in the range from 3 mIU/m<sup>2</sup> to 14 mIU/m<sup>2</sup>, and wherein said variant of human IL-2 has the ability to promote NK cell expansion and function, said variant having an amino acid sequence having at least 90% sequence identity to the full-length amino acid sequence for human IL-2, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is administered once a week for a period of 4 weeks, and said therapeutically effective dose of said IL-2 or variant thereof is administered three times per week beginning on day 8 of said treatment period.

37. (Withdrawn) The method of claim 36, wherein said therapeutically effective dose of said IL-2 or variant thereof is administered three times a week for a period of 4 weeks beginning on day 8 of said treatment period.

38. (Withdrawn) The method of claim 37, wherein said therapeutically effective dose of said anti-CD20 antibody or fragment thereof is in the range from about 225 mg/m<sup>2</sup> to about 400 mg/m<sup>2</sup> and wherein said therapeutically effective dose of said IL-2 or variant thereof is about 6 mIU/m<sup>2</sup>.

39. (Canceled)

40. (Previously presented) The method of claim 31, wherein said IL-2 or variant thereof is administered as a pharmaceutical composition selected from the group consisting of a monomeric IL-2 pharmaceutical composition, a multimeric IL-2 composition, a lyophilized IL-2 pharmaceutical composition, and a spray-dried IL-2 pharmaceutical composition.

41. (Canceled)

42. (Previously presented) The method of claim 31, wherein said variant is des-alanyl-1, serine-125 human IL-2.

43. (Previously presented) The method of claim 31, wherein said anti-CD20 antibody is an immunologically active chimeric anti-CD20 antibody or fragment thereof.

44. (Previously presented) The method of claim 43, wherein said chimeric anti-CD20 antibody is IDEC-C2B8 or fragment thereof.